— Successful first two HAV implantations in wounded Ukrainian citizens — HAVs were provided under Humacyte’s initiative to assist Ukraine humanitarian medical effort — Provides further real-world evidence of the potential of HAV treatment for trauma DURHAM, N.C., June 21, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally […]
Tag: Humacyte
Humacyte Presents New Immunogenicity Data on Human Acellular Vessels™ (HAVs™)
— Data indicate HAV does not stimulate increase in panel reactive antibodies, an adaptive immune response correlated with increased risk of implant failure — — Data presented today in IMPACT session at American Transplant Congress (ATC) 2022 — DURHAM, N.C., June 08, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company […]
Humacyte First Quarter 2022 Financial Results and Business Update
— Human Acellular Vessels™ (HAVs™) shipped to six hospitals in Ukraine for treatment of civilian and military vascular trauma injuries — — Strengthened leadership team with appointment of Shamik Parikh M.D., as Chief Medical Officer — — Multiple scientific meeting presentations and publications highlighting clinical and preclinical HAV data — — Conference call and live webcast at […]
Humacyte Expands Leadership Team with Appointment of Shamik Parikh, M.D., as Chief Medical Officer
–Seasoned physician, scientist and life science executive brings expertise in clinical research and development across product life cycle– –Key appointment as Humacyte advances HAV through multiple late-stage clinical trials in initial vascular applications– DURHAM, N.C., April 05, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human […]
Humacyte Reports Fourth Quarter and Year End 2021 Financial Results and Provides Business Update
— Advancing late-stage clinical and preclinical programs of the Human Acellular Vessel™ (HAV™) and other engineered tissues across several indications – — Multiple publications and scientific meeting presentations highlighting clinical and preclinical HAV results – — Conference call and live webcast at 8:00 am ET today – DURHAM, N.C., March 29, 2022 (GLOBE NEWSWIRE) — […]
Humacyte Announces Publication of Positive Long-Term Follow-Up Data from Phase 2 Trial of HAV™ for Hemodialysis
— Five-year data demonstrate the potential of the Human Acellular VesselTM (HAV) to be a durable and safe option for vascular access for routine, long-term hemodialysis — — Results published in EJVES Vascular Forum — DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue […]
Humacyte Announces Clinical Case Series Demonstrating Potential of Human Acellular Vessel™ (HAV™) to Expand Opportunities for Limb Salvage in Multiple Complex Vascular Reconstruction Scenarios
– Outcomes of first eight compassionate use cases presented at 46th Annual Winter Meeting of the Vascular and Endovascular Surgery Society – – HAV observed to maintain patency and resist infection in the treatment of critical limb ischemia, infection and vascular trauma – – All patients lacked suitable alternative conduit options – DURHAM, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) […]
Humacyte Announces Presentation of First Preclinical Results of the HAV™ in Coronary Artery Bypass Grafting at Advanced Therapies Week Conference
DURHAM, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the first preclinical results of the use of Humacyte’s Human Acellular Vessel™ (HAV) in coronary artery bypass grafting (CABG) will be presented at the Advanced Therapies Week conference […]
Humacyte Announces the Appointments of Three Surgical and Cardiovascular Opinion Leaders to Advisory Roles
DURHAM, N.C., Dec. 31, 2021 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Surgical Key Opinion Leaders (KOLs) Alan P. Kypson, M.D., FACS; Luigi Pascarella, M.D., FACS; and Todd E. Rasmussen, M.D., FACS, (Col, ret. USAF MC), […]
Humacyte Presents Preclinical Results of Small-Diameter HAV™ for Use as a BTT Shunt in Pediatric Heart Disease at American Heart Association’s Scientific Sessions 2021
— Patency and host cell remodeling of the HAV were observed in all study implants – — Preclinical study is one component of Humacyte’s expansion of the testing of the HAV in a broader cardiac bypass surgery application – DURHAM, N.C., Nov. 16, 2021 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing […]